NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	$ 294,142	$ 248,526	$ 555,137	$ 479,095
Clinical and Manufacturing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	29,994	10,041	57,024	18,869
Clinical and Manufacturing \| Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	22,503	0	36,638	0
Clinical and Manufacturing \| Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	6,006	9,956	16,795	18,472
Clinical and Manufacturing \| Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	1,485	85	3,591	397
External Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	6,080	968	13,433	2,334
External Services \| Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	2,499	0	6,111	0
External Services \| Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	3,492	910	7,233	2,150
External Services \| Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	89	58	89	184
Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	6,262	9,735	11,476	19,458
Other \| Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	1,234	0	1,568	0
Other \| Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	4,786	9,330	8,959	18,693
Other \| Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	$ 242	$ 405	$ 949	$ 765